-5%
Chronic Hepatitis B: Sebivo is indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Sebivo:
This indication is based on virologic, serologic, biochemical and histologic responses in nucleoside treatment naïve adult patients with HBeAg positive and HBeAg negative chronic hepatitis B with compensated liver disease
For HBeAg-positive patients, Sebivo should only be initiated in patients with HBV DNA less than 9 log10 copies per mL and ALT greater than or equal to 2x Upper Limit of Normal (ULN) prior to treatment.
For HBeAg-negative patients, Sebivo should only be initiated in patients with HBV DNA less than 7 log10 copies per mL prior to treatment.
On-treatment response should guide continued therapy
Sebivo has not been evaluated in patients co-infected with HIV, HCV or HDV.
Sebivo has not been evaluated in liver transplant recipients or in patients with decompensated liver disease.
Sebivo has not been studied in well-controlled trials for the treatment of patients with established nucleoside analog reverse transcriptase inhibitor-resistant hepatitis B virus infection, but is expected to be cross-resistant to lamivudine.
The safety and efficacy of Sebivo have not been evaluated in Black/African American or Hispanic patients